Nasal Lymphoma: Symptoms, Causes, Diagnosis & Treatment

Nasal lymphoma is a cancer of the immune system that arises in the lining of the nasal cavity, and the most common and aggressive form is extranodal NK/T-cell lymphoma, nasal type, a disease strongly tied to the Epstein-Barr virus. It tends to mimic ordinary sinus problems for weeks or months before the true diagnosis surfaces, which makes it one of the more treacherous cancers an ear-nose-throat specialist can encounter. Although rare in Western countries, it is far more common in East Asia and Latin America, and the treatment approach has shifted dramatically over the past two decades.

What Nasal Lymphoma Actually Looks Like

The symptoms of nasal lymphoma overlap almost entirely with those of a stubborn sinus infection, and that is precisely what makes it dangerous. Patients typically show up with a blocked nose, thick or bloody discharge, and sometimes facial swelling or headache. In a series of 15 patients with nasal NK/T-cell lymphoma, nasal obstruction was the most frequent complaint at roughly 87%, followed by purulent nasal discharge in about 73% and nosebleeds in 60%.¹ Another study catalogued a broader symptom list that also included post-nasal drip, a neck mass, orbital symptoms, fever, and unexplained weight loss.²

What stands out is how unremarkable these complaints sound. A person with a stuffy nose and occasional bloody mucus is far more likely to have allergies or a bacterial infection than cancer. And because nasal lymphoma is uncommon, clinicians often try several rounds of antibiotics or antifungals before considering a biopsy. One case report describes a patient who was treated for fungal rhinosinusitis before anyone suspected lymphoma, underscoring how easily the disease hides behind more familiar diagnoses.³

There are red flags, though. Symptoms that do not respond to standard treatments, tissue that looks necrotic on examination, progressive destruction of the midline structures of the face, and the combination of nasal symptoms with unexplained fevers or weight loss should all raise suspicion. Even on imaging, the disease can masquerade as aggressive fungal sinusitis or a condition called granulomatosis with polyangiitis, because all three can cause tissue death, bone erosion, and fat infiltration around the sinuses.⁴

The Epstein-Barr Virus Connection

Nearly all cases of nasal NK/T-cell lymphoma test positive for the Epstein-Barr virus (EBV), the same virus responsible for mononucleosis. EBV infects the vast majority of the world’s population at some point, usually without lasting consequence. But in a small number of people, the virus appears to drive malignant transformation of NK cells or certain T cells in the nasal mucosa. Research has shown that EBV-positive nasal T-cell lymphomas likely originate from NK-like T cells or gamma-delta T cells, and that the virus itself plays a direct role in turning those cells cancerous.⁵

Why only certain people develop the disease remains an open question, but geography and ethnicity clearly matter. In East Asia and Latin America, nasal NK/T-cell lymphoma can account for upward of 10% of all non-Hodgkin lymphomas, whereas in the United States, Canada, and Europe it represents well under 1%.⁶ A large retrospective analysis from Latin America confirmed the same pattern, noting both the geographic and ethnic predilection of the disease.⁷ The reasons for this disparity are not fully understood, though genetic susceptibility in certain populations and possibly varying strains of EBV have been proposed.

Genetic Pathways That Drive the Cancer

Beyond EBV, researchers have identified several molecular pathways that fuel nasal NK/T-cell lymphoma. The JAK/STAT signaling pathway is one of the most frequently disrupted. A study found mutations in STAT3, BCOR, and MLL2 were the most common genetic alterations, with JAK/STAT pathway genes affected in over half of tumor samples and histone-modifying genes affected in about 38%.⁸ Separate work showed that STAT3 is constitutively switched on in these lymphoma cells and acts as an oncogenic driver. When researchers blocked STAT3 activity, the cancer cells stopped growing and began to die.⁹

JAK3 mutations have also been identified in a subset of patients. In one study, about 7% of patients carried activating JAK3 mutations, and those mutations made cancer cells grow independently of normal growth signals. The JAK3 inhibitor tofacitinib was able to shut down that growth in laboratory experiments, which opens the door to targeted therapy for patients who carry these mutations.¹⁰ These findings do not yet translate directly to everyday clinical care, but they are shaping the next generation of clinical trials.

Two Main Subtypes and Why It Matters

Not every lymphoma in the nose behaves the same way. The two broad categories are NK/T-cell lymphomas and B-cell lymphomas, and they differ in who they affect, where they tend to grow, and how they respond to treatment. NK/T-cell lymphomas favor the nasal cavity itself, while B-cell lymphomas (most commonly diffuse large B-cell lymphoma) more often originate in the nasopharynx. A population-based comparison found that the average age at diagnosis was about 52 for nasal NK/T-cell lymphoma versus about 68 for sinonasal diffuse large B-cell lymphoma. The survival gap was stark: five-year disease-specific survival was roughly 31% for NK/T-cell cases compared with about 64% for the B-cell cases.¹¹

From a pathology standpoint, NK/T-cell lymphoma cells typically express cytotoxic markers, and a newer marker called granulysin has emerged as a useful diagnostic tool. In one study, about 71% of nasal NK/T-cell lymphoma samples expressed granulysin, and it was even detectable in nearly a third of cases that lacked the traditional cytotoxic markers.¹² That additional diagnostic handle is useful because biopsies from the nose often contain heavy inflammation and necrotic debris, which can obscure the malignant cells.

B-cell lymphomas of the sinuses, by contrast, have seen improving survival over recent decades, partly thanks to the addition of rituximab to chemotherapy. Survival outcomes for NK/T-cell lymphomas have not shown the same upward trend, though treatment changes discussed below have made real inroads.¹³

How the Diagnosis Is Made

A tissue biopsy is the only way to confirm nasal lymphoma. Because the tumors tend to be necrotic, the first biopsy sometimes comes back inconclusive, and repeat biopsies are not unusual. The pathologist looks for a characteristic pattern: infiltrating lymphoid cells destroying the surrounding tissue, typically with positivity for EBV and cytotoxic markers on special stains.

Once the diagnosis is confirmed, staging determines how far the disease has spread and guides treatment decisions. PET/CT scanning has become the preferred imaging tool. In a head-to-head comparison, PET/CT detected malignant lesions with about 98% sensitivity versus roughly 81% for conventional methods. In over a fifth of patients, PET/CT changed the assigned disease stage, and it affected treatment planning in about 44% of cases.¹⁴

Blood-based testing for circulating EBV DNA has also become an important part of both staging and monitoring. Higher levels of EBV DNA in the blood before treatment predict worse outcomes. In one prospective study, patients with detectable plasma EBV DNA before treatment had a three-year overall survival of about 43%, compared with about 94% for those without detectable virus. The study concluded that plasma EBV DNA was a strong independent predictor of both treatment response and survival.¹⁵ After treatment, a rise in circulating EBV DNA is one of the earliest signals that the disease is coming back: patients whose EBV DNA turned positive again during follow-up had a relapse rate of over 50%, versus 14% in those whose virus remained undetectable.¹⁶

Prognostic Scoring Systems

Doctors use several risk-scoring tools to estimate outlook and tailor treatment intensity. The Prognostic Index for Natural Killer Lymphoma (PINK) is one widely adopted system. It considers factors like age, disease stage, involvement of distant lymph nodes, and non-nasal disease. A refined version, PINK-B, adds serum beta-2 microglobulin to the score, which helps split patients who would otherwise all be lumped into the high-risk group into more meaningful categories with genuinely different outcomes.¹⁷

A nomogram-revised risk index (NRI), validated in a large cohort of over 1,500 patients, has shown better discrimination than both the Ann Arbor staging system and the original PINK score for predicting overall survival.¹⁸ For the individual patient, the practical takeaway is that prognosis depends on a constellation of factors, not just the cancer’s stage, and that newer scoring systems can help oncologists decide whether to escalate or de-escalate treatment.

Treatment for Localized Disease

The treatment landscape for nasal NK/T-cell lymphoma has changed considerably. In earlier decades, oncologists treated it the way they treated most non-Hodgkin lymphomas: with anthracycline-based chemotherapy regimens like CHOP. The results were poor. These tumors often express a drug-efflux pump called P-glycoprotein, which actively pumps anthracyclines out of the cancer cells. One study found that the complete response rate in P-glycoprotein-positive patients was only 20%, versus 60% in those without the pump.¹⁹

The current standard for localized (stage I-II) disease is a combination of non-anthracycline chemotherapy and radiation. Regimens built around L-asparaginase, etoposide, and sometimes gemcitabine have largely replaced the old anthracycline protocols.²⁰ Radiation is a potent weapon against these tumors and can produce rapid local responses. The two most common ways to combine chemotherapy and radiation are the “sandwich” approach (some chemotherapy, then radiation, then more chemotherapy) and the sequential approach (all chemotherapy first, then radiation). A multicenter retrospective study of over 200 patients found that both strategies achieved high complete response rates of about 87% across the cohort.²¹

Options for Advanced or Relapsed Disease

When the disease is advanced at diagnosis or returns after initial treatment, the situation becomes considerably harder. Intensive salvage chemotherapy regimens like SMILE (a cocktail of steroids, methotrexate, ifosfamide, L-asparaginase, and etoposide) are often used, but outcomes remain poor for many patients.

Immune checkpoint inhibitors have generated real excitement. Pembrolizumab, an anti-PD-1 antibody, has shown activity in patients who have failed multiple lines of chemotherapy. In a small series of seven heavily pretreated patients, four responded, including two complete responses.²² A systematic review that pooled case reports of PD-1 blockade in relapsed or refractory NK/T-cell lymphoma found an overall response rate of about 85% and a complete response rate of about 62%, with responses lasting anywhere from two to 48 months.²³ These numbers are encouraging, though the evidence comes mostly from case reports and small series rather than randomized trials, so the true long-term picture is still taking shape.

Stem cell transplantation is another option for patients who respond to salvage therapy but are at high risk of relapsing again. Both autologous (using the patient’s own stem cells) and allogeneic (using a donor’s cells) transplants have been used. A study of allogeneic transplant in advanced cases found that patients who went into transplant with their disease already in remission fared much better than those transplanted while the lymphoma was still progressing. Seven of eight patients who entered transplant in complete or partial response became long-term survivors, whereas all patients transplanted with progressive disease died of their cancer.²⁴ The takeaway is that getting the disease under control before transplant is critical.

Hemophagocytic Syndrome as a Complication

One of the most feared complications of nasal NK/T-cell lymphoma is hemophagocytic lymphohistiocytosis (HLH), a condition in which the immune system spirals out of control, attacking the body’s own blood cells. In a study of 295 nasal NK/T-cell lymphoma patients, about 7% developed HLH. Those who did had a drastically worse prognosis: after the onset of HLH, no patient in the series survived beyond three months, with a median survival of just 35 days. Risk factors for developing HLH included bone marrow involvement, an enlarged liver or spleen, and elevated lactate dehydrogenase levels.²⁵

HLH can sometimes be the presenting feature that leads to the lymphoma diagnosis. One case report describes a woman with recurrent sinusitis who developed high fevers, plummeting blood counts, and skyrocketing ferritin levels. Her bone marrow showed the telltale immune-cell overactivation of HLH, and further workup revealed the underlying nasal NK/T-cell lymphoma. Treatment with the M-SMILE chemotherapy regimen followed by radiation and an autologous stem cell transplant ultimately brought her into complete remission.²⁶ The case illustrates both how devastating this complication can be and how aggressive treatment can occasionally overcome it.

Midline Destruction and Local Complications

Before the disease was well understood, doctors used the term “lethal midline granuloma” to describe what nasal NK/T-cell lymphoma can do to the face. The tumor erodes cartilage and bone in the center of the face, destroying the nasal septum, palate, and surrounding structures. This destructive pattern has been recognized as part of a spectrum of lymphoproliferative disorders that share a tendency toward devastating midline tissue loss.²⁷

In some patients, the tumor erodes all the way through the hard palate, creating a perforation between the mouth and nasal cavity. A case report describes exactly this: imaging revealed a mass extending from the nasal cavity and maxillary sinus through the hard palate into the oral cavity, with a visible perforating ulcer on the roof of the mouth.²⁸ These complications underscore why early diagnosis matters: the longer the disease goes unrecognized, the more structural damage it inflicts, and rebuilding the midface after treatment is a significant surgical challenge.

Life After Treatment

For patients who achieve remission, the news is mixed. The disease may be gone, but treatment leaves a mark. A cross-sectional study of 310 disease-free survivors of early-stage nasal NK/T-cell lymphoma found that the most common lingering symptoms after radiation were nasal problems (about 50%), dry mouth (about 45%), and dental issues (about 41%). Sensory problems and reduced sexual interest affected a smaller but meaningful proportion. The severity of these symptoms diminished over time and generally plateaued about two years after treatment.²⁹ Whole-neck irradiation was independently linked to worse dry-mouth problems, while patients over 60 were more likely to report reduced sexual interest.

Newer radiation techniques aim to reduce these side effects. A phase 2 trial using intensity-modulated radiation with three dose gradients reported favorable long-term quality of life in patients who remained disease-free, with nasal discomfort being the most common symptom and no grade 3 or 4 toxicities observed.³⁰ Broader research on sinonasal cancers in general confirms that quality of life tends to be worst around the time of diagnosis and treatment, then gradually improves over the following months, though patients who had more extensive surgery or received radiation to a wider field tended to recover more slowly.³¹

Nasal Lymphoma in Cats

This is one of those unusual diseases that also has a well-recognized veterinary counterpart. Nasal lymphoma is the most common nasal tumor in cats, and the parallels with the human disease are loose but interesting. In cats, it is typically a B-cell lymphoma rather than an NK/T-cell lymphoma, and EBV is not a factor. Treatment usually involves radiation, sometimes combined with chemotherapy. In a study of 19 cats treated with both, the median survival was over 31 months, which is considered a strong result for feline cancer. The most important negative prognostic factor was destruction of the cribriform plate, the thin bone separating the nasal cavity from the brain.³² A larger study of 32 cats treated with stereotactic radiation confirmed that cribriform lysis and any extension into the skull cavity predicted much shorter survival times.³³ For cat owners, the practical message is that nasal lymphoma is treatable, especially when caught before it breaches the cribriform plate, but chronic nasal symptoms after treatment are common and should be expected.